Economic Consequences of IPR Infringements - Pharmaceutical Industry in the EU

| June 21, 2017

article image
The use of counterfeit pharmaceuticals and fake medicine can have negative effects on one’s health, and may even lead to death. IPR infringement in the Pharmaceutical industry in the EU also has massive economic consequences, a study by the European Union Intellectual Property Office (EUIPO) has revealed.

Spotlight

PHOENIX All-in-One

All-in-One: Our expertise and coverage for the success of manufacturer partners to provide manufacturer partners a unified approach to the European and all 26 local markets, the PHOENIX group has brought the service brand “All-in-One” into life. All-in-One grants a direct access for manufacturers to patients. With its eight focus areas from a Pan-European Preferred Partnerships, Healthcare Logistics, Business Intelligence, Patient Services to Supply Chain Optimization, Sales Support, Clinical Trial Supply Services and Services for Specialty Drugs, All-in-One has an unparalleled service to manufacturer partners throughout Europe. You do your core business – we care about the rest Our full-service offering enables manufacturers to focus on their core competencies – developing and successfully commercializing innovative products and solutions. We care about the rest. “All-in-One is more than just a collection of services, it is a unified approach to patients all over Europe”, says Stefan

OTHER ARTICLES

What do you have to lose taking hydroxychloroquine for coronavirus? Potentially your life

Article | April 10, 2020

The president and some of his close advisors — desperate for a COVID-19 cure — are asking “What do you have to lose?” by taking hydroxychloroquine (HCQ), a strong medication never adequately tested for efficacy or safety in COVID-19 patients. The correct answer to the president’s question, which he doesn’t seem to want to hear, is that we have our lives to lose. The president acknowledges “I’m not a doctor” but this raises the question “What do doctors know about the drug recommended by the president? Most doctors are aware that HCQ can be effective for patients with malaria, arthritis or lupus. If they were to follow the president’s suggestion and prescribe it for COVID-19 patients, they would also like to know that it will benefit some of those patients, at least.

Read More

WANT LESS “LIABILITY” AND MORE “RELIABILITY” FROM YOUR CLINICAL MOBILITY SOLUTION?

Article | April 10, 2020

I recently discussed the different ways that consumer-grade smartphones can compromise patients’ health, safety and overall care. However, some clinicians and healthcare administrators have indicated in recent months that they need help selecting the right enterprise-grade mobility solutions for their unique operating models and workflows. There are many different hardware and software options, and a single rugged device can come in multiple configurations. So, how do you know if you’re picking the right communication tools for your clinicians? The key is to first set performance expectations for the total mobility solution rather than the device alone.

Read More

Tips for Managing Chronic Pain Beyond Prescription Painkillers

Article | April 10, 2020

Painkillers like Oxycontin, Percocet, and Vicodin, have been prescribed by primary physicians, surgeons, dentists, and other healthcare providers to patients suffering from varying levels of pain. Though these medications have proven to be an effective source of pain relief, they have also proven to be highly addictive. In fact, it has even been reported that there are more cases of a drug overdose and deaths from prescription painkillers than heroin or cocaine. While there are a number of factors that play into this opioid epidemic, educating doctors and patients on alternative solutions to managing chronic pain is a great place to start combatting this nationwide crisis.

Read More

Do Clinical Trial Delays Mean Trouble for Pharmaceutical Stocks?

Article | April 10, 2020

Pharmaceutical stocks have been somewhat of a safe haven for investors as the coronavirus outbreak spread from China to the rest of the world. But as the pandemic deepened, now resulting in more than 782,000 cases worldwide, even these "safer" companies are beginning to feel the effects. The U.S. is now the coronavirus epicenter, with the most cases -- more than 161,000 as of today. Initial concerns for drugmakers had to do with the supply of active pharmaceutical ingredients, which often come from China. The worry was that pharmaceutical companies wouldn't be able to produce enough of their drugs for patients.

Read More

Spotlight

PHOENIX All-in-One

All-in-One: Our expertise and coverage for the success of manufacturer partners to provide manufacturer partners a unified approach to the European and all 26 local markets, the PHOENIX group has brought the service brand “All-in-One” into life. All-in-One grants a direct access for manufacturers to patients. With its eight focus areas from a Pan-European Preferred Partnerships, Healthcare Logistics, Business Intelligence, Patient Services to Supply Chain Optimization, Sales Support, Clinical Trial Supply Services and Services for Specialty Drugs, All-in-One has an unparalleled service to manufacturer partners throughout Europe. You do your core business – we care about the rest Our full-service offering enables manufacturers to focus on their core competencies – developing and successfully commercializing innovative products and solutions. We care about the rest. “All-in-One is more than just a collection of services, it is a unified approach to patients all over Europe”, says Stefan

Events